The 421-01-02 study is a clinical research study that will assess the safety and effectiveness of an investigational drug (lonigutamab) as a potential new treatment for patients with active thyroid eye disease (TED). Lonigutamab is a new drug which may help relieve the symptoms of thyroid eye disease.
Principal Investigator: Dr Jean-Louis DeSousa
ClinicalTrials.gov Identifier: NCT05683496
To enquire further about this study, please contact the Clinical Trials office on (08) 9381 0750, or email firstname.lastname@example.org.